One of the most popular targets in drug development, representing about a third of existing drugs, are G-protein coupled receptors — the tiny but integral membrane proteins responsible for recognizing things like light, taste, smell, hormones and pain.
But due to challenges in mapping their structure, the protein family remains largely unexplored.
A slate of companies has emerged over the last few years to change that. If one can figure out the structure of these elusive membrane receptors, it might be possible to create small molecule drugs that overcome the limitations of, say, biologic and peptide therapies. That promise is what gets serial entrepreneur Raymond Stevens out of bed in the morning.
Article From & Read More ( Breaking: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long term viability remain - Endpoints News )https://ift.tt/3lVxnFw
Business
Bagikan Berita Ini
0 Response to "Breaking: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long term viability remain - Endpoints News"
Post a Comment